Funding for this research was provided by:
Received: 25 July 2022
Accepted: 5 December 2022
First Online: 15 December 2022
: The study was approved by the Stockholm Regional Ethics Committee (reference numbers 2020–02917 and 2013/2206–31).
: Not applicable.
: AstraZeneca was the sponsor of this study. J.B. is a full-time employee of AstraZeneca. J.W.E. has received reimbursement for consultancies or research support from Novo Nordisk, Merck Sharp & Dohme, Boehringer Ingelheim, Ilya Pharma and AstraZeneca. A.N. has received honoraria from MSD, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Novo Nordisk. M.T. is employed by an independent statistical consultant company, Statisticon AB, of which AstraZeneca Nordic-Baltic is a client. D.N. has received consultancy fees from Novo Nordisk, AstraZeneca, and Eli Lilly. T.N. has received unrestricted grants from AstraZeneca and Novo Nordisk and has served on national advisory boards of Novo Nordisk, Sanofi-Aventis, Eli Lilly, MSD and Boehringer Ingelheim. V.R. has received honoraria from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim on expert group participation. No other potential conflicts of interest relevant to this article were reported.